Toward a more comprehensive approach to protecting human subjects: The interface of data safety monitoring boards and institutional review boards in randomized clinical trials

IRB Ethics and Human Research

Volumn 20, Issue 1, 1998, Pages 1-5

  Gordon, Valery M ^a   Sugarman, Jeremy ^b   Kass, Nancy ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVISORY COMMITTEE; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; DRUG INDUSTRY; ETHICS; GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE ORGANIZATION; HUMAN EXPERIMENT; METHODOLOGY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; RANDOMIZATION; RISK; RISK ASSESSMENT; SOCIAL CONTROL; STANDARD; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; NATIONAL INSTITUTES OF HEALTH;

ADVISORY COMMITTEES; CLINICAL TRIALS DATA MONITORING COMMITTEES; COMMITTEE MEMBERSHIP; DRUG INDUSTRY; ETHICAL REVIEW; ETHICS; ETHICS COMMITTEES; ETHICS COMMITTEES, RESEARCH; FEDERAL GOVERNMENT; GOVERNMENT; GOVERNMENT REGULATION; GUIDELINES; HUMAN EXPERIMENTATION; MULTICENTER STUDIES; NATIONAL INSTITUTES OF HEALTH (U.S.); ORGANIZATION AND ADMINISTRATION; RANDOM ALLOCATION; REFERENCE STANDARDS; RESEARCH DESIGN; RISK; RISK ASSESSMENT; SOCIAL CONTROL, FORMAL; UNITED STATES;

EID: 0031611062     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: 10.2307/3564020     Document Type: Article

References (28)

1. 45 CFR 46, revised 18 June 1991.
2. Advisory Committee on Human Radiation Experiments. The Human Radiation Experiments. New York: Oxford University Press, 1996.
3. Federal policy for the protection of human subjects ("Common Rule"). Federal Register 1991; 56:28002.
4. Meinert C. Controlled Clinical Trials. New York: Oxford University Press, 1986.
5. Sackett D. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown, 1991.
6. Schafer A. The ethics of the randomized clinical trial. NEJM 1982; 307:719-24.
7. Freedman B. Equipoise and the ethics of clinical research. NEJM 1987; 317:141-5.
8. Heart Special Project Committee to the National Advisory Heart Council. Organization, review, and administration of cooperative studies (Greenberg Report). Controlled Clinical Trials 1988; 9:137-48.
9. Levine RJ. Ethics and Regulation of Clinical Research. 2nd ed. New Haven: Yale University Press, 1986.
10. Friedman L, DeMets D. The data monitoring committee: how it operates and why. IRB 1981; 3(4):6-8.
11. DeMets DL, Fleming TR, Whitley RJ, et al. The data and safety monitoring board and Acquired Immune Deficiency Syndrome (AIDS) clinical trials. Controlled Clinical Trials 1995; 16:408-21.
12. Ellenberg SS, Myers MW, Blackwelder WC, Hoth DF. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases. Statistics in Medicine 1993; 12:461-7.
13. Protection of human subjects; informed consent and waiver of informed consent requirements in certain emergency research; final rules. Federal Register 1996; 61 (192):51498-533.
14. Veatch RM. Longitudinal studies, sequential design, and grant renewals: what to do with preliminary data. IRB 1979; 1(4):1-3.
15. Armitage P. Interim analysis in clinical trials. Statistics in Medicine 1991; 10:925-937.
16. Enas GG, Dornseif BE, Sampson CB, Rockhold FW, Wuu J. Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry. Controlled Clinical Trials 1989; 10:57-70.
17. Heath EJ. The IRB's monitoring function: four concepts of monitoring. IRB 1979; 1(5):1-3,12.
18. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases. DMID Guidelines for Data and Safety Monitoring Boards. Bethesda, Md.: National Institutes of Health, 21 April 1993.
19. National Heart, Lung, and Blood Institute. NHLBI Guide for Data and Safety Monitoring Boards. Bethesda, Md.: National Institutes of Health, 1995.
20. George SL. A survey of monitoring practices in cancer clinical trials. Statistics in Medicine 1993; 12: 435-50.
21. Geller NL, Stylianou M. Practical issues in data monitoring of clinical trials: summary of responses to a questionnaire at NIH. Statistics in Medicine 1993; 12:543-51.
22. Hawkins BS. Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. roles and membership of data monitoring committees for trials sponsored by the National Eye Institute. Controlled Clinical Trials 1991; 12:424-37.
23. Herson J. Data monitoring boards in the pharmaceutical industry. Statistics in Medicine 1993; 12:555-61.
24. Williams GW, Davis RL, Getson AJ, et al. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view. Statistics in Medicine 1993; 12:481-92.
25. Amdur RJ, Bankert E. Continuing IRB review when research activity is limited to routine follow-up evaluations. IRB 1997; 19(1):7-10.
26. Gordon B, Prentice E. Continuing review of research involving human subjects: approach to the problem and remaining areas of concern. IRB 1997; 19(2):8-11.
27. Phillips DF. Institutional review boards under stress: will they explode or change? JAMA 1996; 276: 1623-6.
28. DeMets DL, Williams GW, Brown BW, the NOTT Research Group . A case report of data monitoring experience: the nocturnal oxygen therapy trial. Controlled Clinical Trials 1982; 3:113-24.